Literature DB >> 34619575

The biological and pharmacological connections between diabetes and various types of cancer.

Xuechang Wang1, Suming Ding2.   

Abstract

Diabetes and cancer incidence have risen tremendously over the years. Additionally, both cancer and diabetes share numerous risks, such as overweight, inactive lifestyles, older age, and smoking. Numerous methods have been suggested to connect obesity and diabetes to cancer advancements, such as increasing insulin/ Insulin-like growth factor I (IGF-1) signaling, lipid and glucose uptake and metabolism, shifts in the cytokine, chemokine, and adipokine profile also variations in the adipose tissue immediately adjacent to cancer spots. Diabetes has been found to have a complicated cancer-causing mechanism involving excessive reactive oxygen species (ROS) production, loss of critical macromolecules, chronic inflammation, and delayed repair, all of which contribute to carcinogenesis. Diabetes-associated epithelial-to-mesenchymal transition and endothelial-to-mesenchymal transition lead to the formation of cancer-associated fibroblasts in tumors by enabling tumor cells to extravasate via the endothelium and epithelium. This study aims to describe the correlation between diabetes and cancer, as well as summarize the molecular connections and shared pathways such as sex hormones, hyperglycemia, inflammation, insulin axis, metabolic symbiosis, and endoplasmic reticulum (ER) stress that exist between them.
Copyright © 2021 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Biologic pathway; Cancer; Diabetes; Insulin; Malignancy

Mesh:

Substances:

Year:  2021        PMID: 34619575     DOI: 10.1016/j.prp.2021.153641

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

1.  Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease.

Authors:  Michihiro Iwaki; Takaomi Kessoku; Kosuke Tanaka; Anna Ozaki; Yuki Kasai; Atsushi Yamamoto; Kota Takahashi; Takashi Kobayashi; Asako Nogami; Yasushi Honda; Yuji Ogawa; Kento Imajo; Shunsuke Oyamada; Noritoshi Kobayashi; Shinichi Aishima; Satoru Saito; Atsushi Nakajima; Masato Yoneda
Journal:  JGH Open       Date:  2022-08-24

2.  Exploring biomarkers and transcriptional factors in type 2 diabetes by comprehensive bioinformatics analysis on RNA-Seq and scRNA-Seq data.

Authors:  Yalan Huang; Linkun Cai; Xiu Liu; Yongjun Wu; Qin Xiang; Rong Yu
Journal:  Ann Transl Med       Date:  2022-09

Review 3.  Metformin: A promising drug for human cancers.

Authors:  Hongnian Wu; Dan Huang; Hong Zhou; Xueqin Sima; Zhe Wu; Yanling Sun; Long Wang; Ying Ruan; Qian Wu; Feng Wu; Tonghui She; Ying Chu; Qizhi Huang; Zhifeng Ning; Hao Zhang
Journal:  Oncol Lett       Date:  2022-05-12       Impact factor: 3.111

Review 4.  Insulin-like growth factor-1 signaling in the tumor microenvironment: Carcinogenesis, cancer drug resistance, and therapeutic potential.

Authors:  Armel H Nwabo Kamdje; Paul F Seke Etet; Maulilio J Kipanyula; Lorella Vecchio; Richard Tagne Simo; Alfred K Njamnshi; Kiven E Lukong; Patrice N Mimche
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-09       Impact factor: 6.055

5.  Plasma prostasin: a novel risk marker for incidence of diabetes and cancer mortality.

Authors:  Xue Bao; Biao Xu; Iram Faqir Muhammad; Peter M Nilsson; Jan Nilsson; Gunnar Engström
Journal:  Diabetologia       Date:  2022-08-04       Impact factor: 10.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.